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duction in aneurysmal tissue are the resident mesenchymal
cells and the invading inflammatory cells. Secreted as inac-
tive zymogens, MMPs must be proteolytically processed
into their active forms. Additionally, their activity after
activation is controlled through binding and inhibition by
specific endogenous tissue inhibitors of the MMPs
(TIMPs).5
A number of MMPs have been implicated in aneurysm
pathogenesis by their presence in AAA tissue including
MMP-1,6,7 MMP-2,8-10 MMP-3,11 MMP-9,3,12 MMP-
12,13 and MMP-13.14 Evidence suggesting a causal role of
MMPs in AAAs has been derived by means of animal mod-
els in which aneurysm formation can be inhibited by syn-
thetic MMP inhibitors15 and overexpression of TIMPs.16
Additionally, the development of experimental AAAs is
suppressed in MMP-9–deficient mice.17 Among members
of the MMP family, MMP-2 is particularly interesting
because of its capability to degrade key structural proteins
of the aorta, fibrillar collagens,18 and elastin.19 Recent
work in our laboratory has demonstrated an increase in
total MMP-2 in AAA tissue compared with nonaneurys-
mal aorta with arteriosclerotic occlusive disease (AOD)
and normal aortic tissue.8 Perhaps more important, there
was a significant increase in the active 62-kd form of
MMP-2, which was bound tightly to matrix, probably
through its fibronectin-like binding domains.20,21 MMP-
2 is secreted as a latent 72-kd proenzyme and must be
converted into the 62-kd form by removal of the amino-
Abdominal aortic aneurysms (AAAs) are a common
and lethal disease characterized by the degradation of
important structural macromolecules, including fibrillar
collagens and elastin. In addition, there is an extensive
inflammatory infiltrate present in the outer media and
adventitia of the aneurysmal wall, consisting largely of T
lymphocytes and macrophages.1-4 These architectural
changes suggest a role for enzymes capable of degrading
matrix proteins. Matrix metalloproteinases (MMPs) are a
group of structurally related, zinc-dependent endopepti-
dases that together can degrade all of the components of
the extracelluar matrix.5 Potential sources of MMP pro-
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Background and Objective: Matrix metalloproteinase–2 (MMP-2) degrades both fibrillar collagens and elastin. MMP-2
is secreted as a latent 72-kd proenzyme that must be proteolytically processed to the 62-kd active form. In our labora-
tory we demonstrated a significant increase of active, matrix-bound MMP-2 in abdominal aortic aneurysmal (AAA) tis-
sue compared with nonaneurysmal aorta with arteriosclerotic occlusive disease and normal aortic tissue. This increase
in active MMP-2 is considered to be important in aneurysm pathogenesis, but the mechanism of its activation in aor-
tic tissue is unknown. Membrane type-1 MMP (MT-1 MMP) is known to be an activator of MMP-2. The purpose of
this study was to determine MT-1 MMP expression and its involvement in pro–MMP-2 activation in human aneurys-
mal tissue.
Methods: Infrarenal aortic tissue was obtained during the surgical repair of AAAs or the bypass of aortoiliac occlusive
disease, or from nondiseased aorta, and the expression of MT-1 MMP messenger RNA was determined with Northern
blot analysis. MT-1 MMP protein was determined with immunoblot and immunohistochemistry. The ability of aortic
tissue to activate pro–MMP-2 was analyzed by incubating aortic tissue with exogenous radiolabeled pro–MMP-2.
Results: MT-1 MMP messenger RNA and protein are increased in AAA (P < .05) compared with arteriosclerotic occlu-
sive disease and normal aortic tissue. Immunohistochemical analysis localized MT-1 MMP to aortic smooth muscle cells
and macrophages in aneurysmal tissue. AAA tissue demonstrated a greater capacity to activate exogenous pro–MMP-2
compared with atherosclerotic and normal aortic tissue (P < .05).
Conclusion: These studies demonstrate that MT-1 MMP is increased in AAA tissue and suggest that it may be impor-
tant in AAA pathogenesis through its ability to activate pro–MMP-2. (J Vasc Surg 2001;34:316-22.)
terminal peptide. Because the 62-kd form is the active
form of the enzyme, elucidation of the mechanism leading
to MMP-2 activation in aneurysmal tissue is important in
the understanding of the pathogenesis of AAA and other
chronic inflammatory diseases associated with matrix
destruction. The structure of pro–MMP-2 was recently
determined with x-ray crystallography,22 which revealed
how the propeptide shields the catalytic domain. The
mechanism of MMP-2 activation differs from those of
other MMPs in that serine proteases such as plasmin and
MMP-3 fail to activate pro–MMP-2.23 These observations
were clarified by learning that the loops connecting the
helices in the propeptide domain of pro–MMP-2 are dif-
ferent from those of other MMPs.22 These loops are
important sites that are cleaved on proteolytic activation.
Earlier studies had shown that activation of MMP-2 took
place at the plasma membrane in fibroblasts and neoplastic
cells treated with concanavalin A or a phorbol ester.24-27
The explanation for this localization of MMP-2 activation
became clear with the discovery of a membrane-bound or
membrane type-1 (MT-1) MMP.28 Other reported activa-
tors of pro–MMP-2 are MMP-1 and MMP-7,29 reactive
oxygen species,30 and thrombin,31 although thrombin
may exert its effects through MT-1 MMP.
In this study, we examined the expression of MT-1
MMP in human aneurysmal tissue. MT-1 MMP messen-
ger RNA (mRNA) and protein are increased in AAA tissue
compared with atherosclerotic, nonaneurysmal aorta, and
normal aortic tissue. Immunohistochemical analysis local-
ized MT-1 MMP to both aortic smooth muscle cells
(SMCs) and macrophages. We also demonstrated that
AAA tissue had a far greater ability to activate exogenous
pro–MMP-2 compared with atherosclerotic and normal
aortic tissue. The results of this study implicate MT-1
MMP as the physiologic activator of MMP-2 in aneurys-
mal tissue and, thus, suggest a role for MT-1 MMP in
AAA pathogenesis.
METHODS
For detailed methods, please see the appendix, online
only.
Human aortic tissue collection. Infrarenal aortic tis-
sue was obtained during surgical repair of an AAA or the
bypass of aortoiliac occlusive disease, or from nondiseased
control aorta (NOR) at organ procurement for transplan-
tation after a protocol approved by the Institutional
Review Board and Research Committee of the University
of Nebraska Medical Center.
Cell cultures. SMC and adventitial fibroblast cell
lines were established from normal infrarenal aortic speci-
mens with the use of previously described techniques.32
For the expression of MT-1 MMP by inflammatory cells
to be assessed, human monocytes and peripheral blood
lymphocytes were separated and purified by countercur-
rent centrifugal elutriation of peripheral blood mononu-
clear cells from leukophoresis of healthy donors. The
monocytes were allowed to differentiate for 5 days in cul-
ture with macrophage colony-stimulating factor. Lipo-
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polysaccharide (LPS, 10 µg/mL) (Sigma Chemical Co, St
Louis, Mo) and phytohemagglutinin (PHA, 1 µg/mL)
(Sigma) were used to activate the macrophages and lym-
phocytes, respectively.
Immunoblot analysis. Aortic tissue was pulverized
in liquid nitrogen, lyophilized, and homogenized in a
buffer containing 1% Triton X-100/50 mmol/L Tris-HCl
(pH 7.5)/0.15 mol/L NaCl/0.05% Brij 35/0.02% NaN3
including the proteinase inhibitors, 10 µmol/L E-64 and
2 mmol/L PMSF (all reagents from Sigma). Equivalent
amounts of protein were loaded (20 µg per lane) and elec-
trophoresed on 10% SDS polyacrylamide gels. After SDS-
PAGE, the proteins were transferred onto nitrocellulose
membranes (Bio-Rad, Hercules, Calif). Immunoblots
were incubated with anti–MT-1 MMP, made in rabbit
against the peptide R (160) EVPYAYIREGHEK (173)
(antibody from H. Nagase). Primary antibody was
detected by probing with a species-specific secondary anti-
body followed by chemiluminescence (ECL, Amersham,
Arlington Heights, Ill) and autoradiography. Images were
quantitated and analyzed with Multi-Analyst/PC Image
Analysis Systems (Bio-Rad).
Reverse transcriptase-polymerase chain reaction
Fig 1. Quantification of MT-1 MMP mRNA in aortic tissue.
MT-1 MMP mRNA was compared for AAA, AOD, and normal
aortic tissue (5 patients per group) with Northern blot analysis.
Transcripts for MT-1 MMP and β-actin were detected at 4.5 kb
and 2.0 kb, respectively. Intensity of β-actin transcripts in normal
and AOD groups are increased over AAA group because of
increased exposure time required for visualization of MT-1 MMP
transcripts. Results indicate twofold increase of MT-1 MMP
mRNA expression in AAA over both AOD and normal aortic tis-
sue. Data shown are mean values (± SEM) with representative
lanes compiled from same blot below. Asterisk indicates AAA
greater than NOR and AOD with ANOVA (P < .05).
and Southern blot analysis. Cultured macrophages,
lymphocytes, SMCs, and fibroblasts were lysed in 1 mL of
Trizol (GibcoBRL, Gaithersburg, Md) per 30 × 106 cells.
RNA was extracted according to the manufacturer’s
instructions. Complementary DNA (cDNA) was amplified
28 cycles with polymerase chain reaction (PCR) condi-
tions consisting of denaturation at 94°C for 30 seconds,
annealing at 50°C for 30 seconds, and extension at 72°C
for 60 seconds with a PEC9600 Perkin-Elmer DNA ther-
mal cycler (Perkin-Elmer Co, Foster City, Calif). The
mRNA for β-actin was amplified by means of each of the
RNA samples to standardize the amount of total RNA
between samples. The PCR products were separated elec-
trophoretically on 2% agarose gels, transferred to Hybond
N nylon membranes (Amersham), and hybridized with
phosphorus 32–end-labeled oligonucleotide probes.
Hybridized bands were visualized with autoradiography.
MT-1 MMP and β-actin primers were synthesized by
GibcoBRL.
Northern blot analysis. Aortic tissue (AAA, AOD,
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NOR; 5 patients in each group) was pulverized in liquid
nitrogen, and total RNA was extracted for Northern Blot
analysis as previously described.8 Equivalent amounts (10
µg) of RNA were resolved on agarose-formaldehyde gels
and transferred onto Nytran membranes (Amersham
Pharmacia Biotech, Piscataway, NJ). MT-1 MMP tran-
scripts were standardized to β-actin and expressed as the
mean ± SE.
Immunohistochemistry. Dual immunohistochem-
istry was performed on paraffin-embedded sections of
human aortic tissue cut into 4-µm sections. The sections
were incubated with a polyclonal MT-1 MMP antibody
(Chemicon International Inc, Temecula, Calif) at a dilu-
tion of 1:250. MT-1 MMP antibody was visualized with a
Texas-red fluorescent-conjugated secondary antibody
(Southern Biotech Assoc Inc, Birmingham, Ala). MT-1
MMP protein was expressed in both mononuclear inflam-
matory cells and mesenchymal cells. The inflammatory
cells were identified by means of a 1:400 dilution of 
polyclonal lysozyme antibody (Dako Corp, Carpinteria,
Calif) visualized with fluorescein isothiocyanate (FITC)–
conjugated secondary antibody (Southern Biotech). The
mesenchymal cells were determined to be SMCs with
SMC-specific α-actin antibody (Dako Corp) visualized
with FITC-conjugated antibody (Southern Biotech).
Antibody staining was visualized with a Zeiss confocal
immunofluorescent microscope (Carl Zeiss, Inc, Thorn-
wood, NY). Digital images were processed with Adobe
Photoshop 3.0 software (Adobe Systems Inc, Mountain
View, Calif).
Iodine 125 labeling of pro–MMP-2. Purified
recombinant pro–MMP-2 (Calbiochem, San Diego, Calif)
was labeled with the IODO-GEN iodination reagent kit
(Pierce, Rockford, Ill) with 1 mCi of 125I reagent
(Amersham) per 5 µg of protein. Unbound 125I was sepa-
rated on Sephadex G-25 columns (Amersham Pharmacia
Biotech). The labeled MMP-2 had a specific activity of 3.3
× 105 cpm/µL.
Processing of pro–MMP-2 by aortic tissue. 125I-
labeled pro–MMP-2 was incubated at 37°C for 14 hours
with AAA, AOD, and normal aortic tissue extracts (tissue
from 5 patients in each group). Equivalent dry weights (5
mg) of lyophilized aortic tissue were extracted with 50
mmol/L Tris-HCl (pH 7.5)/0.15 mol/L NaCl/0.05%
Brij 35, 10 µmol/L E-64, and 2 mmol/L PMSF. An
equivalent amount of pro–MMP-2 was added to each of
the extracts. The reaction mixtures were incubated
overnight in the presence of serine and cysteine proteinase
inhibitors. Reaction products were analyzed with SDS-
PAGE followed by autoradiography. 125I-labeled
pro–MMP-2 was activated by 1 mmol/L APMA (Sigma)
at 37°C for 2 hours and run as a positive control. The neg-
ative control was 125I–pro–MMP-2 incubated at 37°C in
the same reaction conditions but without tissue.
RESULTS
Quantification of MT-1 MMP mRNA in aortic tis-
sue. mRNA levels of MT-1 MMP were assessed in AAA,
Fig 2. Quantification of MT-1 MMP protein in aortic tissue.
Protein levels of MT-1 MMP were compared for AAA (n = 10
patients), AOD (n = 10 patients), and normal (n = 8 patients)
aortic tissue with immunoblot analysis. Single band was detected
at 63 kd. Results indicate twofold increase of MT-1 MMP protein
in AAA tissue over AOD and sixfold increase in AAA over normal
aortic tissue. Data shown are mean values (± SEM) with repre-
sentative lanes compiled from same blot below. Asterisk indicates
AOD and AAA greater than NOR with ANOVA (P < .05); plus
sign indicates AAA greater than AOD (P < .05).
AOD, and normal control aorta (tissue from 5 patients in
each group) by Northern blot analysis with equivalent
amounts of RNA per sample (10 µg). Representative sam-
ples (2 of 5) are shown in Fig 1. A single band for MT-1
MMP was detected at 4.5 kilobase (kb). The β-actin tran-
script was detected at 2.0 kb. The mean and SE were
determined for each group and compared by means of
analysis of variance (ANOVA). There was a twofold
increase (P < .05) in standardized MT-1 MMP mRNA
expression in the AAA (mean = 0.1732) group over both
AOD (mean = 0.0984) and normal aortic tissue (mean =
0.0862). MT-1 MMP transcripts did not differ signifi-
cantly between the AOD and normal aortic groups.
Quantification of MT-1 MMP protein in aortic
tissue. Equivalent protein amounts (20 µg) of AAA,
AOD, and normal aortic tissue extracts were analyzed with
Western immunoblot. Representative lanes are shown in
Fig 2. A single band of approximately 63 kd was detected.
By intergroup statistical analysis of MT-1 MMP protein
levels, all three groups were statistically different (P < .05),
with a twofold increase in AAA over AOD tissue (mean of
0.315 vs 0.145) and a sixfold increase in AAA over normal
aortic tissue (mean of 0.0537).
MT-1 MMP mRNA expression by aortic mes-
enchymal cells and inflammatory cells. Total RNA
was extracted for reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis from each of the cell types
found in AAA tissue. Southern blot analyses of the RT-
PCR products are shown in Fig 3. Primers for the β-actin
gene were used in the RT-PCRs with the same RNA to
demonstrate equal concentration of RNA among the
samples. MT-1 MMP mRNA expression was found in
aortic SMCs, adventitial fibroblasts, and monocytes, with
increased expression seen in differentiated macrophages
and stimulated macrophages. MT-1 MMP mRNA was
not detected in lymphocytes unless they were stimulated
with PHA.
Localization of MT-1 MMP protein in AAA.
Paraffin-embedded sections of aneurysm tissue were incu-
bated with MT-1 MMP antibody to determine the cellu-
lar location of MT-1 MMP protein. MT-1 MMP protein
was expressed in both mononuclear inflammatory cells
(Fig 4, A) and spindle-shaped mesenchymal cells (Fig 4,
D) in aneurysmal tissue. The mononuclear cells were
determined to be macrophages as confirmed with the use
of lysozyme antibody (Fig 4, B) and visualized with FITC-
conjugated secondary antibody. The mesenchymal cells
were determined to be SMCs with SMC-specific α-actin
antibody (Fig 4, E) visualized with FITC-conjugated sec-
ondary antibody. Colocalization dual fluorescent
immunohistochemical analysis documented the presence
of MT-1 MMP in the cytoplasm of aortic SMCs with
dense staining in the perinuclear region (red stain). SMC-
specific α-actin staining was seen more centrifugally in
these same cells (green stain; Fig 4, F). Adjacent sections
of the outer media and adventitia were used to colocalize
MT-1 MMP with lysozyme antibody. Lysozyme is specific
for neutrophils as well as monocytes. Through careful
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morphologic analysis, these cells were found to be mono-
cytes/macrophages. Furthermore, in previous studies
neutrophils have not been identified in nonruptured AAA
tissue.1 MT-1 MMP was located in the perinuclear region
of macrophage cells as demonstrated by the overlapping
stain with lysozyme antibody (Fig 4, C). The presence of
MT-1 MMP staining in the cytoplasm rather than at the
cell membrane was unexpected because it is assumed to be
functionally active as a membrane-bound enzyme. This
probably reflects an increased concentration of the protein
in its intracellular location relative to the amount
expressed on the cell surface.
AAA tissue activation of 125I-labeled pro–MMP-2.
Equivalent amounts (by dry weight) of AAA, AOD, and
normal aortic tissue were incubated with exogenous 125I-
labeled pro–MMP-2 overnight at 37°C. There were a total
of five different samples for each aortic group. Each tissue
sample was incubated separately with equivalent concen-
trations of pro–MMP-2. The percent of pro–MMP-2 acti-
vated over total MMP-2 (mean ± SEM) by the aortic
groups was determined, and lanes are shown in Fig 5. The
results indicate that AAA tissue has a far greater ability
(threefold) to activate the exogenous 125I-labeled
pro–MMP-2 (P < .05). There were no differences between
the AOD and normal aortic tissue groups in MMP-2 
activating ability. 125I-labeled pro–MMP-2 incubated in
the same reaction conditions without tissue was not acti-
vated. We attempted without success to block this activa-
tion using two different MT-1 MMP antibodies. The
treatment of SMCs with concanavalin A results in the acti-
vation of pro–MMP-2 through the induction of MT-1
MMP.24-27 These MT-1 MMP antibodies also failed to
block this MT-1 MMP-mediated activation of pro–MMP-
2. Furthermore, the inability of these antibodies to block
Fig 3. MT-1 MMP mRNA expression by aortic mesenchymal
cells and inflammatory cells. Total RNA extracted from cell types
present in aneurysmal tissue was subjected to RT-PCR with
primers specific for MT-1 MMP and β-actin. Amplification prod-
ucts were detected with Southern hybridization with 32P–end-
labeled oligonucleotide probes. Lane 1, RT-PCR products from
monocytes; Lane 2, differentiated macrophages; Lane 3, LPS-acti-
vated macrophages; Lane 4, PBLs; Lane 5, PHA-activated PBLs;
Lane 6, aortic infrarenal SMCs; Lane 7, aortic infrarenal adventi-
tial fibroblasts. RT-PCR was performed with identical RNA sam-
ples with primers to β-actin sequence to demonstrate equal
concentration of RNA per sample.
MT-1 MMP activation of MMP-2 has been noted by other
groups.33 The contribution of serine and cysteine proteases
can be excluded because the incubations were performed
in the presence of the inhibitors PMSF and E-64.
DISCUSSION
Our results demonstrate increased levels of MT-1
MMP in AAA tissue and implicate it as a major physiologic
activator of MMP-2 in aneurysmal tissue. Northern blot
analysis of MT-1 mRNA expression in aortic tissue corre-
lated with the immunoblot protein data suggesting that
protein levels are controlled pretranslationally. Although
our data do not exclude the possibility that other members
of the membrane-bound MMPs or additional proteinases
may also be contributing to MMP-2 activation, we did not
detect MT-2 MMP or MT-3 MMP protein in aortic tissue
with immunoblot analysis (data not shown). Additional
data supporting a predominant role of MT-1 MMP in
proMMP-2 activation were demonstrated by Rajavashisth
et al33 through in vitro studies. With the immunodeple-
tion of MT-1 MMP protein from membrane lysates of
human vascular SMCs, a substantial portion of the proteo-
lytic activation of exogenous pro–MMP-2 was blocked.
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Most convincingly, little pro–MMP-2 activation can be
found in concanavalin-treated skin fibroblasts isolated
from MT-1 MMP deficient mice, when compared with
control-stimulated mice fibroblasts (K. Holmbeck, written
communication, June 2001).
Chronic inflammation in the outer media and adven-
titia of the aorta is also a prominent feature of AAA, sug-
gesting that immune cells may participate in the
connective tissue destruction associated with aneurysmal
degeneration. About 50% to 70% of the inflammatory cells
are T lymphocytes with the remainder consisting of
macrophages and B lymphocytes.1,34 Henderson et al4
recently suggested that the ratio of macrophages to lym-
phocytes might be closer to 1:1. Leukocytes produce
cytokines, which induce resident mesenchymal cells to
produce MMPs.35 The proinflammatory macrophage
cytokines, interleukin-1 and tumor necrosis factor α, can
stimulate MMP production by SMCs.35-37 These
cytokines are present in aneurysmal tissue.34 In addition,
Schonbeck et al38 have demonstrated that the CD40-L
expressed on T lymphocytes promotes the expression of
MMPs in SMCs, including secretion of active MMP-2.
With immunohistochemistry we have demonstrated the
Fig 4. MT-1 MMP immunolocalization to macrophages and aortic SMCs in AAA tissue. Localization of MT-1 MMP protein in
aneurysmal tissue was determined with double fluorescent immunohistochemical analysis to determine cell types expressing MT-1 MMP
protein. MT-1 MMP protein was expressed in both mononuclear inflammatory cells (A) and spindle-shaped mesenchymal cells (D) in
aneurysmal tissue. Mononuclear cells were determined to be macrophages by means of an antibody to lysozyme (B) visualized with
FITC-conjugated secondary antibody. Mesenchymal cells were determined to be SMCs with SMC-specific α-actin antibody (E) visual-
ized with FITC-conjugated secondary antibody. A, MT-1 MMP protein (red stain) localized to perinuclear region of macrophages (thick
white arrows). B, Same section of AAA tissue stained for lysozyme (green stain) in perinuclear area. C, Dual labeling for MT-1 MMP
protein and lysozyme demonstrates colocalization of two antibodies. D, Adjacent section of aneurysmal tissue with fewer inflammatory
cells and residual elastin lamellae localizes MT-1 MMP protein (red stain) to spindle-shaped mesenchymal cells (thin white arrows). E,
Cells of same spindle shape (thin white arrows) stained positive for SMC-specific α-actin (green stain) in granular pattern with centrifu-
gal location in cells. White arrow head denotes residual elastic lamellae, which show homogeneous pattern of autofluorescence at this
wavelength. F, Adjacent section double stained with MT-1 MMP and SMC-specific α-actin antibodies.
presence of MT-1 MMP protein in aortic SMCs in
aneurysmal tissue. In some sections, MT-1 MMP staining
in SMCs appears most intense in areas where these mes-
enchymal cells are surrounded by inflammatory cells, sug-
gesting that the inflammatory cell milieu contributes to
MT-1 MMP upregulation in vivo.
Besides inducing mesenchymal cell expression of
MMPs, inflammatory cells produce their own MMPs.
Macrophages can secrete MMP-1, MMP-2, MMP-3,
MMP-7, MMP-9, and MMP-12.39,40 Secretion of high
levels of MMPs, especially MMP-9 and MMP-12 by the
inflammatory cells, could also contribute to the overall
proteolytic state of the tissue. Freestone et al9 suggest that
inflammation in the adventitia contributes to AAA growth.
Expression of interleukin-2 receptors and HLA-D439
demonstrates activation of these immune cells in AAA tis-
sue. In addition to mesenchymal expression of MT-1 MMP
mRNA, we show expression of MT-1 MMP transcripts by
macrophages in vitro. LPS-activation increases macrophage
expression of MT-1 MMP mRNA. Lymphocytes only
express MT-1 MMP after stimulation. In agreement with
the in vitro mRNA data, we show by immunohistochem-
istry that macrophages are an important source of MT-1
MMP in aneurysmal tissue. The expression of MT-1 MMP
by macrophages has also recently been identified in
periprosthetic tissues41 as well as alveolar macrophages in
emphysematous lung.42 Our finding of MT-1 MMP
expression in macrophages of AAA tissue suggests an
important mechanism for local tissue destruction by invad-
ing macrophages. We have previously demonstrated that a
significant proportion of latent pro–MMP-2 in normal
aorta and active MMP-2 in diseased aorta is matrix
bound.8 Itoh et al43 suggest that the fibronectin-binding
domains of MMP-2 allow it to be located on the matrix
before its activation. This may be important not only for
targeting the enzyme to a specific location in the tissue, but
also for stabilizing the active enzyme. The invading
macrophages, therefore, can provide the MT-1 MMP for
this local activation and matrix destruction.
In addition to its role in activating pro–MMP-2, MT-1
MMP is capable of degrading types I, II, and III collagen,
as well as gelatin, fibronectin, vitronectin, and laminin-1.44
It has recently been shown that MT-1 MMP has a pivotal
role in degradation of fibrillar collagens. Holmbeck et al45
demonstrated that MT-1 MMP has a critical role in growth
and development using MT-1 MMP–deficient mice. These
mice have a severe phenotype due to the ablation of a col-
lagenolytic activity. These studies show that MT-1 MMP
activity cannot be adequately compensated by other mem-
brane-type MMPs, other MMPs, or other collagen-degrad-
ing enzymes. Thus, MT-1 MMP could have a direct role in
degradation of the fibrillar collagen matrix of the media and
adventitia in AAA.
Increased levels of MT-1 MMP in aneurysmal tissue
may be important in AAA pathogenesis by activating
pro–MMP-2 and directly degrading matrix. The results of
our study suggest that the increase of activation of MMP-
2 in AAA compared with AOD is due to an increase in
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MT-1 MMP expression. Expression of MT-1 MMP in
macrophages, along with MMP-2–producing mesenchy-
mal cells, suggests a role for synergistic matrix destruction.
MT-1 MMP may be an important therapeutic target for
AAA and other chronic inflammatory diseases associated
with matrix destruction.
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